Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Feb

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Adjuvant Durvalumab in Resected Early-Stage NSCLC

Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25

AACR Announces Fellows of the AACR Academy Class of 2026

Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer

Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett Esophagus Esophageal Cancer